No CrossRef data available.
Article contents
Inhibiteurs calciques et troubles de l’humeur: une revue de la littérature
Published online by Cambridge University Press: 28 April 2020
Résumé
Les auteurs présentent une synthèse des études publiees sur l’effet thérapeutique des inhibiteurs calciques, en particulier du vérapamil, dans les troubles dysthymiques. L’ensemble des observations rapportées regroupe un total de 109 patients présentant un état maniaque ou hypomaniaque d’intensité modérée, d’apparition spontanée ou induite par les antidépresseurs, traités sur des durées s’échelonnant entre 14 jours et 18 mois. Ces études objectivent une action prophylactique du vérapamil au moins égale à celle du lithium et une action curative antimaniaque plus rapide qu’avec le lithium. Le vérapamil est souvent efficace chez les patients résistants au lithium et a l’avantage de ne pas nécessiter de surveillance régulière des taux plasmatiques. Il s'avère régulièrement inefficace chez les patients qui sont à la fois résistants au lithium et à la carbamazépine. C’est dans le traitement et la prévention des virages maniaques induits par les antidépresseurs que l’action du vérapamil est la plus manifeste. L'action antimaniaque d’autres inhibiteurs calciques (diltiazem, groupe des dihydropyridines) a été beaucoup moins étudiée. Il ressort que les inhibiteurs calciques peuvent constituer une alternative intéressante aux autres régulateurs thymiques dans le traitement des troubles de l’humeur ; toutefois, la toxicité cardio-vasculaire et neurologique de leur association au lithium ou aux bêta-bloquants mérite d’être mieux appréciée. L’intérêt de telles substances dans le traitement des troubles dépressifs est très discutable, la prise d’inhibiteurs calciques ayant même été incriminée dans l’apparition d’une dépression chez des patients normothymiques. Quelques-unes des propriétés et des interactions entre calcium, lithium, neuromédiateurs et inhibiteurs calciques sont évoquées.
Summary
A review of the studies published on the therapeutic effects in mood disorders of calcium antagonists, and in particular of verapamil, is presented. The cases reported in the literature amount to a total of 109 patients presenting with a manic or hypomanic syndrome of moderate intensity, of spontaneous onset or induced by antidepressants, treated for periods ranging from 14 d to 18 mths. These studies indicate a preventive action of verapamil, at least equal to that of lithium, and a more precocious curative action on the manic symptoms than that obtained with lithium. Verapamil is often efficient in patients resistent to lithium and has the advantage of not requiring supervision of serum concentrations. It regularly proves inefficient in patients resistent to both lithium and carbamazepine. The action of verapamil is most evident in the treatment and prevention of antidepressants induced switches into mania. Far fewer studies have been carried out on the action of other calcium antagonists (diltiazem, dihydropyridine group). Hence, calcium antagonists may constitute an interesting alternative to other mood regulators in affective disorders; nevertheless, their cardiovascular and neurological toxicity, when co-administered with lithium or beta blockers requires further investigation. The value of such substances for the treatment of depression is much less evident and treatment with calcium antagonists has even been accused of inducing depression in normothymic subjects. Certain properties and interactions between calcium, lithium, neuromediators and calcium antagonists are evoked.
Keywords
- Type
- Revue
- Information
- Copyright
- Copyright © European Psychiatric Association 1990
References
Références
Barton, BMGitlin, MJ (1987) Verapamil in treatment resistant mania: an opcn tria. J Clin Psychopharmacol 7, 101–103CrossRefGoogle Scholar
Beigel, AMurphy, DLBunney, WE Jr (1960) The Manic State Rating Scale: Scale construction, reliability and validity. Arch Gen Psychiatry 25, 256–262CrossRefGoogle Scholar
Brisac, AMLaurent, S (1988) Inhibiteurs calciques et système nerveux central. La lettre du Pharmacologue 2, 175–178Google Scholar
Brotman, AWFarhadi, AMGelenberg, AJ (1986) Verapamil treatment of acute mania. J Clin Psychiatry 47, 136–138Google ScholarPubMed
Bushe, CJ (1985) Organic psychosis caused by diltiazem. J Royal Soc Med 81, 296CrossRefGoogle Scholar
Caillard, VMasse, G (1982) Traitement de la manie par un inhibiteur calcique: étude préliminaire. Encéphale 8, 587–594Google Scholar
Caillard, VLeroy, MCRoume, DMasse, GRopert, R (1982) Traitement de l’excitation maniaque par un inhibiteur calcique. Nouv Presse Med 11, 1012–1013Google Scholar
Caillard, V (1985) Treatment of mania using a calcium antagonist: preliminary trial. Neuropsychobiol 14, 23–26CrossRefGoogle ScholarPubMed
Carlen, PLGurevich, NDurand, D (1982) Ethanol in low doses augments calcium mediated mechanisms measured intra-cellulary in hippocampal neurons. Science 215, 306–310CrossRefGoogle ScholarPubMed
Carman, JSPost, RMRunkle, DCBunney, WE JrWyatt, RJ (1979) Increased serum calcium and phosphorous with the switch into manic or excited psychotic States. Br J Psychiatry 135, 55–61CrossRefGoogle ScholarPubMed
Carman, JSWyatt, RJ (1979a) Use of calcitonin in psychotic agitation or mania. Arch Gen Psychiatry 136, 72–75CrossRefGoogle Scholar
Carman, JSWyatt, RJ (1979b) Calcium : Bivalent actions in the bivalent psychoses. Biol Psychiatry 14, 295–336Google Scholar
Cortes, RSupavilai, PKarobath, MPalacios, JM (1984) Calcium antagonist binding sites in the rat brain : quantitative autoradiographic mapping using the 1-4 dihydropyrine [3H] PN200-110 and [3H] PY 108-068. J Neural Transm 60, 169–197CrossRefGoogle Scholar
Dolin, SLittle, HHudspith, M (1987) Increased dihydropyridine-sensitive calcium channels in rat brain may underlie ethanol physical dependence. Neuropharmacology 26, 275–279CrossRefGoogle ScholarPubMed
Dose, MEmrich, HMCording-Tômmel, CVon Zerssen, D (1986) Use of calcium antagonist in mania. Psychoneuroendocrinology 11, 241–243CrossRefGoogle ScholarPubMed
Dubovsky, SLFranks, RDLifschitz, MLCohen, P (1982) Effectiveness of verapamil in the treatment of a manic patient. Am J Psychiatry 139, 502–504Google ScholarPubMed
Dubovsky, SLFranks, RD (1983) Intracellular calcium ions in affective disorders. Biol Psychiatry 18, 781–797Google ScholarPubMed
Dubovsky, SLFranks, RDSchrier, D (1985) Phenelzine - induced hypomania: effect of verapamil. Biol Psychiatry 20, 1009–1014CrossRefGoogle ScholarPubMed
Dubovsky, SLFranks, RDAllen, SMurphy, J (1986) Calcium antagonists in mania: a double-blind study of verapamil. Psychiatry Res 18, 309–320CrossRefGoogle ScholarPubMed
Dubovsky, SLFranks, RDAllen, S (1987) Verapamil: a new antimanic drug with potential interactions with lithium. J Clin Psychiatry 48, 371–372Google ScholarPubMed
Giannini, AJExtein, IGold, Set al (1983) Clonidine in mania. Drug Dev Res 3, 101–103CrossRefGoogle Scholar
Giannini, AJHouser, WL JrLoiselle, RHGiannini, MCPrice, WA (1984) Anitmanic effects of verapamil. Am J Psychiatry 141, 1602–1603Google ScholarPubMed
Giannini, AJLoiselle, RHPrice, WAGiannini, MC (1985) Comparison of antimanic efficacy of clonidine and verapamil. J Clin Pharmacol 25, 307–308CrossRefGoogle ScholarPubMed
Giannini, AJTaraszewski, RLoiselle, RH (1987) Verapamil and lithium in maintenance therapy of manic patients. J Clin Pharmacol 27, 980–982CrossRefGoogle ScholarPubMed
Gitlin, MJWeiss, J (1984) Verapamil as maintenance treatment in bipolar illness: a case report. J Clin Psychopharmacol 4, 341–343CrossRefGoogle ScholarPubMed
Groat, RDMackenzie, TB (1980) The appearance of mania following intravenous calcium replacement. J Nerv Ment Dis 168, 562–563CrossRefGoogle ScholarPubMed
Hoffmeister, FBenz, UHeisse, AKrause, HPNeuser, V (1982) Behavioral effects of nimodipine in animais. Arzneim-Forsch 4, 347–360Google Scholar
Höschl, CBlahos, JKabes, J (1986) The use of calcium channel blockers in psychiatry. In: Proceeding of the IVth World congress in Psychiatry. Developments in psychiatry (Shagass ed). Elsevier Science, New York, pp 329–331Google Scholar
Hullett, FJPotkin, SGLevy, ABCiasca, R (1988) Depression associated with nifedipine-induced calcium channel blockade. Am J Psychiatry 145, 1277 1279Google ScholarPubMed
Jacobsen, FMSack, DAJames, SP (1987) Delirium induced by verapamil. Am J Psychiatry 144, 248Google ScholarPubMed
Jouvent, RLecrubier, YPuech, AJ (1980) Antimanic effects of clonidine. Am J Psychiatry 137, 1275–1276Google Scholar
Kennedy, SOzersky, SRobillard, M (1986) Refractory bipolar illness may not respond to verapamil. J Clin Psychopharmacol 6, 316–317Google Scholar
Lorr, MKlett, J (1967) Impatient Multidimensional Psychiatric Scale (IMPS), Consulting Psychologist Press, Palo AltoGoogle Scholar
Macphee, GJAMcInnes, GTThompson, GGBrodie, MJ (1986) Verapamil potentiates carbamazepine neurotoxicity : a clinically important inhibitory interaction. The Lancet March 29, 700–703CrossRefGoogle Scholar
Martin, PLaurent, SMassol, JChilds, MPuech, AJ (1989) Effects of dihydropyridine drugs on reversal by imipramine of helpless behavior in rats. European J Pharmacol 162, 185–188CrossRefGoogle ScholarPubMed
Mathis, PSchmitt, LMoron, P (1988) Efficacité du vérapamil dans les accès maniaques. Encéphale, XIV, 127–132Google Scholar
Middlemiss, DNSpedding, MA (1985) Functional correlate for the dihydropyridine binding site in rat brain. Nature 314, 94–96CrossRefGoogle ScholarPubMed
Overall, JEGorham, DR (1962) The brief psychiatric rating scale. Psychol Rep 10, 799–812CrossRefGoogle Scholar
Palat, GKHooker, EAMovahed, A (1984) Secondary mania associated with diltiazem. Clin Cardiol 7, 611 612CrossRefGoogle ScholarPubMed
Patterson, JF (1987) Treatment of acute mania with verapamil. J Clin Psychopharmacol 7, 206–207CrossRefGoogle ScholarPubMed
Pickar, DWolkowitz, OMDoran, ARLabarca, RRoy, ABreier, ANarang, PK (1987) Clinical and biochemical effects of verapamil administration to schizophrenic patients. Arch Gen Psychiatry 44, 113–118CrossRefGoogle ScholarPubMed
Pollack, MHRosenbaum, JF (1987) Verapamil in the treatment of recurrent unipolar depression. Biol Psychiatry 22, 776–779CrossRefGoogle ScholarPubMed
Price, WAGiannini, AJ (1986) Neurotoxicity caused by lithium-verapamil synergism. J Clin Pharmacol 26, 717–719CrossRefGoogle ScholarPubMed
Renwart, NFrances, HSimon, P (1986) The calcium entry blockers: antimanic drugs? Prog Neuro-Psychopharmacol & Biol Psychiatry 10, 717–722CrossRefGoogle Scholar
Sandyk, RGillman, MA (1986) How does verapamil exert an antimanic effect? Am J Psychiatry 143, 388Google ScholarPubMed
Solomon, LWilliamson, P (1986) Verapamil in bipolar illness. Can J Psy 31, 442–444CrossRefGoogle ScholarPubMed
Valdiserri, EV (1985) A possible interaction between lithium and diltiazem: case report. J Clin Psychiatry 46, 540–541Google ScholarPubMed
Young, RCBiggs, JTZiegler, VEMeyer, DA (1978) A rating scale for mania: reliability, validity and sensivity. Br J Psychiatry 133, 429–435CrossRefGoogle Scholar
Comments
No Comments have been published for this article.